Clinical decision support that reasons like a cannabis physician: match the indication to the evidence, dose low-and-slow by THC and CBD, screen the psychosis and pregnancy contraindications, and catch the CYP drug interaction — with the decision rule and exactly what would change it. Built for verified physicians.
Two real medical-cannabis questions, each reasoned the way HeyHippocrates answers: the skills fire, the answer is cited, the decision rule is explicit, and what's missing is flagged. Scroll to each.
Refractory neuropathic pain despite standard agents, the patient asking about medical cannabis — how do I prescribe safely?
Chronic neuropathic pain is one of the better-evidenced indications, as an adjunct after standard agents fall short. Screen out the contraindications first — a history of psychosis, pregnancy or breastfeeding, adolescence, unstable cardiovascular disease and cannabis use disorder. Then start low and go slow: a CBD-predominant or balanced product at a low dose, preferring an oral or oromucosal route for steady levels over inhalation, and titrate over weeks to effect and tolerance. Review the CYP drug interactions, set functional goals with a review date, and document informed consent.
Decision ruleNeuropathic pain (reasonable evidence, adjunct) → screen contraindications (psychosis, pregnancy, adolescence, cardiac instability, cannabis use disorder); CBD-predominant or balanced, low dose, oral/oromucosal, titrate over weeks; check CYP interactions; functional goals + consent + review.
Not established from this alone — the indication evidence, the contraindications and the concomitant drugs change the plan.
A 19-year-old with anxiety and a family history of schizophrenia wants THC for sleep — the response?
This is a high-risk candidate for THC. Cannabis, and THC specifically, can precipitate or worsen psychosis, and the risk is highest in adolescents and young adults and in those with a personal or family history of a psychotic disorder. THC can also worsen anxiety rather than relieve it. Advise against THC here, treat the sleep and anxiety with first-line evidence-based measures, and, if a cannabinoid is considered at all, restrict it to a CBD-predominant product with clear counseling and monitoring. Screening out the wrong candidate protects the patient as much as any prescription.
Decision ruleYoung adult + anxiety + family history of schizophrenia → THC contraindicated or high-risk (psychosis precipitation, worse in youth and with family history; THC can worsen anxiety); treat sleep/anxiety with first-line care; only CBD-predominant if any, with counseling.
Not established from this alone — the age, the psychiatric history and the goal change whether any cannabinoid fits.
Illustrative simulations. The physician always decides.
The exact questions your field searches for — answered in the format the knowledge base speaks: the answer, the decision rule, what's missing, and the source.
The evidence is best for a handful of uses: chronic and neuropathic pain as an adjunct, chemotherapy-induced nausea and vomiting refractory to standard antiemetics, spasticity in multiple sclerosis, and — for purified CBD — specific severe childhood epilepsies such as Dravet and Lennox-Gastaut syndromes. Evidence is weaker or mixed for sleep, anxiety and most psychiatric uses, where cannabis may even do harm. Prescribe where the evidence supports it, name the uncertainty elsewhere, and always weigh it against the risks.evidence review
Decision ruleBest evidence: chronic/neuropathic pain (adjunct), refractory chemo-induced nausea and vomiting, MS spasticity, purified CBD for Dravet/Lennox-Gastaut; weak or mixed for sleep, anxiety, most psychiatric uses; prescribe to the evidence, name the uncertainty.
Missing data: the indication, the evidence strength and the alternatives change whether to prescribe.
Start low and go slow. Begin with a low dose of a CBD-predominant or balanced THC-to-CBD product, and add or increase THC gradually only as needed, because THC drives most of the dose-limiting effects. Choose the route for the goal: oral and oromucosal give slow onset and steady, longer-lasting levels suited to chronic symptoms, while inhalation acts fast but is harder to titrate and irritates the airway. Titrate over days to weeks against effect and tolerability, and stop or step back if adverse effects outweigh benefit.dosing guidance
Decision ruleStart low, go slow → low-dose CBD-predominant or balanced first, add THC gradually (THC drives dose-limiting effects); oral/oromucosal for steady chronic control, inhaled for fast but harder-to-titrate; titrate over days to weeks to effect and tolerability.
Missing data: the goal, the product ratio and the tolerability change the dose and the route.
Avoid or use great caution in a personal or family history of psychosis or schizophrenia, since THC can precipitate or worsen it, especially in adolescents and young adults whose developing brains are more vulnerable. Avoid it in pregnancy and breastfeeding. Take care with significant cardiovascular disease, a history of cannabis or other substance use disorder, and severe hepatic impairment. Counsel on driving impairment and the risk of dependence, and reassess anyone whose use is escalating.safety guidance
Decision ruleContraindications/cautions: psychosis or schizophrenia history (THC precipitates, worse in youth), pregnancy/breastfeeding, significant cardiovascular disease, substance use disorder, severe hepatic impairment; counsel on driving and dependence; reassess escalating use.
Missing data: the psychiatric, cardiac and reproductive history change the safety of prescribing.
CBD inhibits several cytochrome P450 enzymes, so it can raise levels of drugs like warfarin, clobazam and some antiepileptics — monitor and adjust. Cannabinoids add to the sedation of opioids, benzodiazepines and alcohol. Common adverse effects are dizziness, dry mouth, cognitive slowing and, with THC, anxiety, tachycardia and orthostatic drops. Watch for cannabinoid hyperemesis syndrome in heavy chronic users presenting with cyclical vomiting, and for the development of cannabis use disorder. Review the full medication list before and during therapy.pharmacovigilance
Decision ruleCBD inhibits CYP → raises warfarin, clobazam, some antiepileptics (monitor/adjust); additive sedation with opioids/benzodiazepines/alcohol; adverse effects dizziness/cognitive/THC anxiety-tachycardia; watch cannabinoid hyperemesis in heavy users and cannabis use disorder.
Missing data: the concomitant drugs, the dose and the use pattern change the interactions and the risks.
Your whole practice, one specialist brain — grounded in champion-authored, cited knowledge.
A generalist medical-cannabis colleague across indications and evidence, dosing and titration, formulation and route, contraindications, interactions and adverse effects — cited, non-directive, always with the decision rule.
Deep specialist agents for pain and palliative indications, neurology and epilepsy, safety and contraindications, and dosing and pharmacology — each its own soul and knowledge base — plus your own uploaded materials.
From the right candidate to the CYP interaction the margin is thin. Only one of these reasons like a medical-cannabis colleague whose every claim you can trace.
The waitlist is a founding cohort. Members shape the medical cannabis build, get in before anyone else, and lock the founding price for good.
Leave your name and work email. We'll reach out the moment medical cannabis opens — with your Founding Cannabis Physician offer.
One email at launch. No spam, ever.
It reasons in the frameworks you use — the evidence-based indications, low-and-slow dosing, the contraindication screen and the cannabinoid drug interactions — and always shows the reasoning, the decision rule and what would change it. The decision always stays your call.
Both. Residents use it to pressure-test a plan and learn the decision rule; attendings use it as a fast, cited second opinion in a fast-moving field. Access is gated to verified physicians.
Pain and palliative indications, neurology and epilepsy, safety and contraindications, and dosing and pharmacology each have their own deep specialist agent on the Pro plan, on top of the full medical-cannabis scope on Basic.
No. It is physician-facing clinical decision support — a cited thinking partner. It does not diagnose, does not treat, and gives no patient-facing advice. The decision always stays with you.
Every answer is grounded only in champion-authored, cited medical-cannabis knowledge — traceable, not hallucinated — and always states the decision rule plus what data is missing, instead of a confident guess.
HeyHippocrates